HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026
Neoadjuvant therapy in gall bladder cancer improves resectability and survival: a prospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lahiri Anupam, Chowdhury Suchita, Goel Shaifali, Assif Iqbal Syed, Aggarwal Abhishek, Garg Prerna, Goel Varun, Talwar Vineet, Sethi Jaskaran, Singh Shivendra
Аннотация
BACKGROUND: Gallbladder carcinoma has dismal prognosis with <20 % resectability at presentation. The role of Neoadjuvant chemotherapy (NACT) remains undefined.
METHODS: This is a prospective single center study of 226 gallbladder carcinoma patients receiving NACT. Gemcitabine-platinum combinations were administered followed by response assessment. Primary endpoints included resectability and survival outcomes.
RESULTS: Of 226 patients, 135 (59.7 %) completed NACT. Intention-to-treat resection rate was 36.2 % (82/226), increasing to 60.7 % (82/135) among treatment completers. R0 resection achieved in 95.1 % (78/82). Grade ≥3 toxicity occurred in 9.7 % with 1.7 % treatment-related mortality. Median overall survival: 27 months (resectable) versus 13 months (unresectable) (p < 0.001). Two-year overall survival: 62.1 % versus 31.4 % respectively. Perioperative mortality: 3.7 %; major morbidity: 13.5 %. Incidental gallbladder cancer showed higher resectability (44.1 % vs 33.7 %) with 2-year overall survival 75 % versus 55.6 %. Multivariate analysis identified resectability (HR 2.714, p = 0.0002), perineural invasion (HR 2.986, p = 0.018), and advanced T-stage (HR 1.940, p = 0.041) as independent prognostic factors.
CONCLUSIONS: NACT enables curative resection in 60.7 % completing treatment with acceptable toxicity, supporting incorporation into treatment algorithms for locally advanced gallbladder cancer.
METHODS: This is a prospective single center study of 226 gallbladder carcinoma patients receiving NACT. Gemcitabine-platinum combinations were administered followed by response assessment. Primary endpoints included resectability and survival outcomes.
RESULTS: Of 226 patients, 135 (59.7 %) completed NACT. Intention-to-treat resection rate was 36.2 % (82/226), increasing to 60.7 % (82/135) among treatment completers. R0 resection achieved in 95.1 % (78/82). Grade ≥3 toxicity occurred in 9.7 % with 1.7 % treatment-related mortality. Median overall survival: 27 months (resectable) versus 13 months (unresectable) (p < 0.001). Two-year overall survival: 62.1 % versus 31.4 % respectively. Perioperative mortality: 3.7 %; major morbidity: 13.5 %. Incidental gallbladder cancer showed higher resectability (44.1 % vs 33.7 %) with 2-year overall survival 75 % versus 55.6 %. Multivariate analysis identified resectability (HR 2.714, p = 0.0002), perineural invasion (HR 2.986, p = 0.018), and advanced T-stage (HR 1.940, p = 0.041) as independent prognostic factors.
CONCLUSIONS: NACT enables curative resection in 60.7 % completing treatment with acceptable toxicity, supporting incorporation into treatment algorithms for locally advanced gallbladder cancer.
Предметные рубрики MeSH
HumansGallbladder NeoplasmsNeoadjuvant TherapyFemaleProspective StudiesMaleAgedMiddle AgedChemotherapy, AdjuvantTreatment OutcomeAntineoplastic Combined Chemotherapy ProtocolsRisk FactorsTime FactorsDeoxycytidineGemcitabineAdultCarcinomaKaplan-Meier EstimateAged, 80 and overMultivariate AnalysisProportional Hazards ModelsCholecystectomy